The treatment of wet AMD in Canada: Access to therapy (policy review)

Canadian Journal of Ophthalmology

Volumn 44, Issue 5, 2009, Pages 548-556

  Cruess, Alan ^a   Maberley, David ^b   Wong, David ^c   Chen, John ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Montreal Retinal and Laser Institute   (Canada)

Author keywords

Access; Blindness; Evaluation; Health care economics; Health care quality; Macular degeneration

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY; NEW DRUG; NUCLEIC ACID; PEGAPTANIB; PROTEIN TYROSINE KINASE INHIBITOR; RANIBIZUMAB; SMALL INTERFERING RNA; VASCULOTROPIN; VERTEPORFIN;

AGED; AGING; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INCIDENCE; LASER COAGULATION; LOW LEVEL LASER THERAPY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PREVALENCE; PRIVATE HEALTH INSURANCE; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

EID: 70349449765     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-140     Document Type: Article

References (40)

1. Anis A. National pharmacare: a dog's tale. CMAJ 2004;171:565-566
2. Cantebury Communications. A clear vision: solutions to Canada's vision loss crisis. Report on symposium. The cost of blindness- what it means to Canadians. Available at: http://www. costofblindness.org. Accessed March 25, 2009.
3. Collier R. Drug development cost estimates hard to swallow. CMAJ 2009;180:279-280
4. Outlook 2009. Boston: Tufts Center for the Study of Drug Development. 2009:2.
5. Tierney M, Manns B; Members of the Canadian Expert Drug Advisory Committee. Optimizing the use of prescription drugs in Canada through the Common Drug Review. CMAJ 2008;178:432-435
6. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Tenyear incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 2002;109:1767-1779 (Pubitemid 35222560)
7. Ambati J, Ambati BK, Yoo SH, Ianchuley S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-293 (Pubitemid 36553096)
8. Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beachamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005;40:277-287 (Pubitemid 40942254)
9. Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol 2007;42:836-843
10. Novack GD. Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 2008;48:61-78. (Pubitemid 351738149)
11. National Eye Institute. National Institutes of Health 2009. Available at: http://www.nei.nih.gov/. Accessed April 20, 2009.
12. AMD Canada. Wet AMD: an overview. Available at: htpp:// www.amdcanada.com. Accessed April 21, 2009.
13. Oliver-Fernandez A, Bakal J, Segal S, Shah GK, Dugar A, Sharma S. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005;40:313-319 (Pubitemid 40942258)
14. Brown MM, Brown GC, Sharma S, Landy J, Bakal J. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120:481-484 (Pubitemid 34727820)
15. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51. (Pubitemid 30036436)
16. Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol 2007;125:1249-1254 (Pubitemid 47403034)
17. Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 2007;91:1303-1307 (Pubitemid 47492861)
18. The National Coalition for Vision Health FAQ. Available at: http://www.visionhealth.ca/faq.htm. Accessed April 20, 2009.
19. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Opthalmol 1999;117:1329-1345
20. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444 (Pubitemid 44511558)
21. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
22. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007;91:1177-1182 (Pubitemid 47344893)
23. Kesen MR, Cousins SW. AMD research: current needs and future directions. AMD Update. Issue 24. 2008. Available at: http://www.lwwvisioncare.com/emails/ amdupdate/index. asp?issue=24. Accessed April 20, 2009.
24. Health Canada. Access to therapeutic products. The regulatory process in Canada: drug submissions. Available at: http://www. hc-sc.gc.ca/ahc-asc/pubs/ hpfb-dgpsa/access-therapeutic-accestherapeutique- eng.php#5.1. Accessed April 17, 2009.
25. Canadian Agency for Drugs and Technologies in Health. CDR process: procedure for common drug review. April 2008. Available at: http://www.cadth.ca. Accessed April 17, 2009.
26. Ontario Ministry of Health and Long-Term Care. How drugs are approved: review process. Ontario Drug Benefit (ODB) Review Process. Available at: http://www.health.gov.on.ca/english/ public/pub/drugs/approved.html. Accessed April 17, 2009.
27. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation and reasons for recommendation. Pegaptanib sodium. May 25, 2006. Available at: http:// www.cadth.ca. Accessed April 21, 2009.
28. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value-based reappraisal with 5-year data. Am J Opthalmol 2005;140:679-687 (Pubitemid 41455310)
29. Canadian Agency for Drugs and Technologies in Health. Technology report: management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation. Issue 43. April 2008. Available at: http://www.cadth.ca. Accessed April 21, 2009.
30. Canadian Agency for Drugs and Technologies in Health. CEDAC final recommendation on reconsideration and reasons for recommendation. Ranibizumab. March 27, 2008. Available at: http://www.cadth.ca. Accessed April 21, 2009.
31. Canadian Agency for Drugs and Technologies in Health. CDR drug plans' response to recommendations of CEDAC. April 27, 2007. Available at: http://www.cadth.ca/index.php/en/cdr/recommendations. Accessed April 20, 2009.
32. Brogan Inc. iMAM Database. September 15, 2008. Availble at: http://www.broganinc.com. Accessed April 17, 2009.
33. IMS-Provincial reimbursement advisor. February 2008;11(1):67-69
34. Health technologies or services awaiting review. Available at: http://www.health.alberta.ca/initiatives/AHTDP-info-reports. html. Accessed April 22, 2009.
35. Saskatchewan Health. Formulary committee bulletin. October 2008. Available at: http://formulary.drugplan.health.gov.sk.ca. Accessed April 21, 2009.
36. Wyatt G, Gladu V, McDonald-Taylor K, et al. The 2007 Wyatt Health international comparison: access to innovative pharmaceuticals: how do countries compare? Wyatt Management Consulting Inc. 2008. Available at: www.wyatthealth.com. Accessed April 21, 2009.
37. Patented Medicine Prices Review Board. Report on new patented drugs: Avastin. Available at: http://www.pmprb-cepmb. gc.ca. Accessed April 17, 2009.
38. AMD Alliance International: AMD information. Treatments and research. Available at: www.amdalliance.org/information/ treatments/treatments/php. Accessed April 21, 2009.
39. National Eye Institute. National Institutes of Health press release. Comparison of AMD Treatments Trial (CATT): Lucentis-Avastin trial. Available at: www.nei.nih.gov/news/ pressreleases/022208.asp. Accessed April 21, 2009.
40. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Opthalmol 2008;145:239-248